International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 550-552 , June 2010

In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii

  • Houmin Li

      Affiliations

    • Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, West District, Beijing 100044, People's Republic of China
    • ,
  • Qiaoyun Lu

      Affiliations

    • Department of Dermatology, Peking University First Hospital, and Research Center for Medical Mycology, Peking University, No. 8 Xishiku Street, West District, Beijing, People's Republic of China
    • ,
  • Zhe Wan

      Affiliations

    • Department of Dermatology, Peking University First Hospital, and Research Center for Medical Mycology, Peking University, No. 8 Xishiku Street, West District, Beijing, People's Republic of China
    • ,
  • Jianzhong Zhang

      Affiliations

    • Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, West District, Beijing 100044, People's Republic of China
    • Corresponding Author InformationCorresponding author. Tel.: +86 10 8832 5471; fax: +86 10 8832 8386.

Received 19 November 2009 ,Accepted 12 January 2010.

References 

  1. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1999;1:247–261
  2. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl. 1):48–66
  3. Tokimatsu I, Karashima R, Yamagata E, Yamakami Y, Nagai H, Kadota J, et al. Pathogenesis of Trichosporon asahii and strategies for infectious control of disseminated trichosporosis. Nippon Ishinkin Gakkai Zasshi. 2003;44:181–186[in Japanese]
  4. Cawley MJ, Braxton GR, Haith LR, Reilly KJ, Guilday RE, Patton ML. Trichosporon beigelii infection: experience in a regional burn center. Burns. 2000;26:483–486
  5. Ebright JR, Fairfax MR, Vazquez JA. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin Infect Dis. 2001;33:E28–30
  6. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7(Suppl. 2):8–24
  7. Moretti-Branchini ML, Fukushima K, Schreiber AZ, Nishimura K, Papaiordanou PM, Trabasso P, et al. Trichosporon species infection in bone marrow transplanted patients. Diagn Microbiol Infect Dis. 2001;39:161–164
  8. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28:1616–1622
  9. Kamberi P, Atsuro H, Takayoshi T, Masaru N. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy. 1998;44:55–62
  10. Serena C, Mariné M, Pastor FJ, Nolard N, Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother. 2005;55:1020–1023
  11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2nd ed. Document M27-A2. Wayne, PA: CLSI; 2002.
  12. Serena C, Pastor FJ, Gilgado F, Mayayo E, Guarro J. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother. 2005;49:497–502
  13. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.. Antimicrob Agents Chemother. 2002;46:245–247

PII: S0924-8579(10)00058-0

doi: 10.1016/j.ijantimicag.2010.01.013

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 550-552 , June 2010

Article Tools